We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
LGC Clinical Diagnostics

Illumina

Illumina develops, manufactures and markets integrated systems for the analysis of genetic variations and biological ... read more Featured Products: More products

Download Mobile App




Gut Microbiome Dysbiosis Characterized in Parkinson’s Disease

By LabMedica International staff writers
Posted on 29 Jun 2020
Print article
Image: The MiSeq Next Generation Sequencer is an integrated instrument that performs clonal amplification, genomic DNA sequencing, and data analysis with base calling, alignment, variant calling, and reporting in a single run (Photo courtesy of Illumina).
Image: The MiSeq Next Generation Sequencer is an integrated instrument that performs clonal amplification, genomic DNA sequencing, and data analysis with base calling, alignment, variant calling, and reporting in a single run (Photo courtesy of Illumina).
Parkinson’s disease (PD) is a common, progressive, and debilitating disease, which currently cannot be prevented or cured. With the exception of rare genetic forms, the cause of PD is unknown. Symptoms start gradually, sometimes starting with a barely noticeable tremor in just one hand. Tremors are common, but the disorder also commonly causes stiffness or slowing of movement.

The emerging information about the importance of the gut microbiome in human health and disease, together with the well-established connection between PD and the gut including common and early occurrence of constipation, inflammation, and increased gut membrane permeability, have raised the possibility that microorganisms in the gut may play a role in PD pathogenesis.

Neurologists at the University of Alabama at Birmingham (Birmingham, AL, USA) and their colleagues conducted a microbiome-wide association study (MWAS) with two large datasets for internal replication (n = 333 and 507). They used uniform methodology when possible, interrogated confounders, and applied two statistical tests for concordance, followed by correlation network analysis to infer interactions. The team used advances in DNA sequencing and computational tools to look for microbial communities that may be associated with PD.

DNA extraction and sequencing of datasets were done in different laboratories, keeping methods uniform as possible. Negative controls were included in both datasets. DNA was extracted using MoBio PowerMag Soil DNA Isolation Kit for dataset 1 and MoBio PowerSoil DNA Isolation Kit for dataset 2, both kits using equivalent chemistries (MoBio Industries, Carlsbad, CA). Hypervariable region 4 (V4) of the bacterial/archaeal 16S rRNA gene was PCR amplified using primers and sequenced using Illumina MiSeq (Illumina, San Diego, CA, USA).

The team discovered a remarkable difference between the two datasets, despite efforts to standardize data collection and analysis. Using network analysis, they found three polymicrobial clusters, and also found that each cluster shared functional characteristics. The first cluster was that of opportunistic pathogens overabundant in PD cases, a novel finding. The other two clusters were confirmatory of previous studies. In comparison to controls, persons with PD had reduced levels of a cluster of microbes that produce short-chain fatty acids. In the third cluster, the persons with PD had elevated levels of two genera that are carbohydrate-metabolizing probiotic microbes.

The investigators reported that five genera had higher abundances in PD than in controls: Porphyromonas, Prevotella, Corynebacterium_1, Bifidobacterium, and Lactobacillus. Ten genera had lower abundances in PD: Faecalibacterium, Agathobacter, Blautia, Roseburia, Fusicatenibacter, Lachnospira, Butyricicoccus, Lachnospiraceae_ND3007_group, Lachnospiraceae_UCG-004, and Oscillospira.

Haydeh Payami, PhD, a Professor of Molecular Genetics and the senior author of the study said, “There is more to be learned, with larger sample sizes with greater power, longitudinal studies to track change from prodromal to advanced disease, and by next-generation metagenome sequencing to broaden the scope from bacteria and archaea to include viruses and fungi, and improve the resolution to strain and gene level.” The study was published on June 12, 2020 in the journal npj Parkinson’s Disease.

Gold Member
Flocked Fiber Swabs
Puritan® Patented HydraFlock®
Verification Panels for Assay Development & QC
Seroconversion Panels
New
Centromere B Assay
Centromere B Test
New
HIV-1 Test
HIV-1 Real Time RT-PCR Kit

Print article

Channels

Molecular Diagnostics

view channel
Image: Researcher Kanta Horie places a sample in a mass spectrometer that measures protein levels in blood plasma and other fluids (Photo courtesy of WashU Medicine)

Highly Accurate Blood Test Diagnoses Alzheimer’s and Measures Dementia Progression

Several blood tests are currently available to assist doctors in diagnosing Alzheimer's disease in individuals experiencing cognitive symptoms. However, these tests do not provide insights into the clinical... Read more

Immunology

view channel
Image: The findings were based on patients from the ADAURA clinical trial of the targeted therapy osimertinib for patients with NSCLC with EGFR-activated mutations (Photo courtesy of YSM Multimedia Team)

Post-Treatment Blood Test Could Inform Future Cancer Therapy Decisions

In the ongoing advancement of personalized medicine, a new study has provided evidence supporting the use of a tool that detects cancer-derived molecules in the blood of lung cancer patients years after... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.